Related references
Note: Only part of the references are listed.Evaluation of the binding performance of flavonoids to estrogen receptor alpha by Autodock, Autodock Vina and Surflex-Dock
Qiao Xue et al.
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY (2022)
Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study
Morgan Caplan et al.
CRITICAL CARE MEDICINE (2021)
In Silico Study Examining New Phenylpropanoids Targets with Antidepressant Activity
Poliane da Silva Calixto et al.
CURRENT DRUG TARGETS (2021)
Valproic Acid Inhibits Chronic Toxoplasma Infection and Associated Brain Inflammation in Mice
Marjan Enshaeieh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Promising Drug Targets and Compounds with Anti-Toxoplasma gondii Activity
Marco da Silva et al.
MICROORGANISMS (2021)
Lignans and Neolignans Anti-tuberculosis Identified by QSAR and Molecular Modeling
Mayara S. Maia et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2020)
Na+/K+-ATPase-Targeted Cytotoxicity of (+)-Digoxin and Several Semisynthetic Derivatives
Yulin Ren et al.
JOURNAL OF NATURAL PRODUCTS (2020)
SWISS-MODEL: homology modelling of protein structures and complexes
Andrew Waterhouse et al.
NUCLEIC ACIDS RESEARCH (2018)
Mycophenolic acid induces differentiation of Toxoplasma gondii RH strain tachyzoites into bradyzoites and formation of cyst-like structure in vitro
Kitzia N. Castro-Elizalde et al.
PARASITOLOGY RESEARCH (2018)
Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro
Joshua B. Radke et al.
ACS INFECTIOUS DISEASES (2018)
Toxoplasma gondii
Joshua A. Kochanowsky et al.
CURRENT BIOLOGY (2018)
Discovery of New Inhibitors of Toxoplasma gondii via the Pathogen Box
Jeremy Spalenka et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Drugs in development for toxoplasmosis: advances, challenges, and current status
P. Holland Alday et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery
Sandra Duffy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Investigation of Calcium Channel Blockers as Antiprotozoal Agents and Their Interference in the Metabolism of Leishmania (L.) infantum
Juliana Quero Reimao et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2016)
Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma gondii Growth
Ashley J. Dittmar et al.
MSPHERE (2016)
Inhibition and Structure of Toxoplasma gondii Purine Nucleoside Phosphorylase
Teraya M. Donaldson et al.
EUKARYOTIC CELL (2014)
Drug repurposing: mining protozoan proteomes for targets of known bioactive compounds
Adam Sateriale et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2014)
Prevalence and genotyping of Toxoplasma gondii in naturally-infected synanthropic rats (Rattus norvegicus) and mice (Mus musculus) in eastern China
Chao Yan et al.
PARASITES & VECTORS (2014)
Potent and Selective Inhibitors of CDPK1 from T. gondii and C. parvum Based on a 5-Aminopyrazole-4-carboxamide Scaffold
Zhongsheng Zhang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Drug repurposing and human parasitic protozoan diseases
Katherine T. Andrews et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2014)
Trophoblast cells are able to regulate monocyte activity to control Toxoplasma gondii infection
A. S. Castro et al.
PLACENTA (2013)
Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice
Amanda J. Payne et al.
PARASITOLOGY RESEARCH (2013)
Discovery of Potent and Selective Inhibitors of Toxoplasma gondii Thymidylate Synthase for Opportunistic Infections
Nilesh Zaware et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Antibiotics for human toxoplasmosis: a systematic review of randomized trials
Senaka Rajapakse et al.
PATHOGENS AND GLOBAL HEALTH (2013)
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Yanti Octavia et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2012)
Digitoxin and its analogs as novel cancer therapeutics
Hosam A. Elbaz et al.
EXPERIMENTAL HEMATOLGY & ONCOLOGY (2012)
Inhibition of DNA Gyrase by Levofloxacin and Related Fluorine-Containing Heterocyclic Compounds
V. L. Tunitskaya et al.
ACTA NATURAE (2011)
MolDock Applied to Structure-Based Virtual Screening
Walter Filgueira De Azevedo
CURRENT DRUG TARGETS (2010)
Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence
Ira J. Blader et al.
APMIS (2009)
An alternative method for the evaluation of docking performance: RSR vs RMSD
Dilmurat Yusuf et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2008)
Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms
Wolf Peter Hofmann et al.
LIVER INTERNATIONAL (2008)
Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents
Stephen P. Muench et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2007)
Cysteine protease inhibitors block Toxoplasma gondii microneme secretion and cell invasion
Chin Fen Teo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
MolDock: A new technique for high-accuracy molecular docking
Rene Thomsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
UCSF chimera - A visualization system for exploratory research and analysis
EF Pettersen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
ATP-induced conformational changes of the nucleotide-binding domain of Na,K-ATPase
M Hilge et al.
NATURE STRUCTURAL BIOLOGY (2003)
Structure validation by Cα geometry:: φ,ψ and Cβ deviation
SC Lovell et al.
PROTEINS-STRUCTURE FUNCTION AND GENETICS (2003)
The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis
TV Aspinall et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Share Paper
